Article
UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study.
Clinical pharmacology and therapeutics - 1 Jul 2012
Wang Y-H, Trucksis M, McElwee J J, Wong P H, Maciolek C, Thompson C D, Prueksaritanont T, Garrett G C, Declercq R, Vets E, Willson K J, Smith R C, Klappenbach J A, Opiteck G J, Tsou J A, Gibson C, Laethem T, Panorchan P, Iwamoto M, Shaw P M, Wagner J A, Harrelson J C
Abstract excerpt
MK-7246, an antagonist of the chemoattractant receptor on T helper type 2 (Th2) cells, is being developed for the treatment of respiratory diseases. In a first-in-human study, we investigated whether genetic polymorphisms contributed to the marked intersubject variability in the pharmacokinetics...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.